Wnt/β-Catenin Signalling during Liver Metabolism, Chronic Liver Disease and Hepatocarcinogenesis

Journal of Renal and Hepatic Disorders

Jully Gogoi-Tiwari^1¹  Sara Pasic^1²  Manoj K Bhat^2³  Gayatri D Shirolkar^1⁴ 

[1] Fremantle and Fiona Stanley Hospitals, Perth, WA, Australia^3;National Centre for Cell Science, Savitribai Phule Pune University Campus, Ganeshkhind, Pune, India^2;School of Medicine and Pharmacology, University of Western Australia, Fremantle, WA, Australia^4;School of Pharmacy and Biomedical Sciences and Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia^1

关键词: chronic liver disease;    hepatocellular carcinoma;    liver progenitor cells;    metabolic syndrome;    Wnt/β-catenin signalling;   

DOI  :  10.15586/jrenhep.2018.29

学科分类：内分泌与代谢学

来源: Codon Publications

【 摘 要 】

Chronic liver diseases (CLDs) are increasing in prevalence and their end-stage complications, namely, cirrhosis, liver failure and hepatocellular carcinoma represent major global challenges. The most common initiators of progressive CLD are viral hepatitis and long-term alcohol abuse as well as steatosis and steatohepatitis. Irrespective of the underlying aetiology, a common feature of CLD is the formation of hepatic ductular reactions, involving the proliferation of liver progenitor cells (LPCs) and their signalling to fibrosis-driving hepatic stellate cells. The Wnt/β-catenin pathway has been found to regulate development, stemness and differentiation, and alterations in its activity have been associated with tumour development. Recent data highlight the role of Wnt/β-catenin signalling in hepatic metabolism, steatosis and cancer, and suggest targeting of this pathway as a promising molecular strategy to potentially inhibit CLD progression and hepatocarcinogenesis.

【 授权许可】

CC BY